- Industrial Alliance Securities set a $5.50 price target for Sensus Healthcare, indicating a potential 89% upside despite recent financial setbacks.
- The company reported a significant drop in Q2 revenue to $2.3 million, primarily due to delayed third-party financing for its SRT-100 systems.
- Sensus Healthcare’s CEO confirmed cutting ties with the problematic bank, with expectations to recognize the delayed revenue in the third quarter.
Sensus Healthcare (NASDAQ:SRTS) is a leading medical device company that develops and sells treatments for cancer and skin conditions. The company has a market capitalization of about $47.9 million. Its stock price currently trades around $2.91 per share, with a 52-week range between $2.66 and $5.49.
On August 17, 2026, Industrial Alliance Securities adjusted its stock price target for Sensus Healthcare to $5.50. At the time, the share price was trading at $2.91 per share. This new target suggests a potential increase of nearly 89% from its current price, indicating a belief in the company’s future performance despite recent challenges.
This adjustment follows the company’s second-quarter financial report. As announced by Businesswire, Sensus Healthcare reported revenue of $2.3 million, a sharp decrease from $7.3 million in the same quarter last year. The company states this drop was caused by a lower number of units sold due to delayed financing from a third-party bank.
According to the Q2 2026 earnings call transcript published by Seeking Alpha, the financing issues prevented Sensus Healthcare from recognizing revenue on eight SRT-100 systems. These medical devices, with an average price of $250,000 each, have since been approved through a different bank. The company now expects to record this revenue in the third quarter.
Following the incident, Chairman and CEO Joe Sardano confirmed the company has cut ties with the bank responsible for the delays. He stated, “We will no longer be working with this bank,” signaling a move to prevent similar issues from affecting future revenue recognition and financial reporting.
